Source:http://linkedlifedata.com/resource/pubmed/id/16784989
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7
|
pubmed:dateCreated |
2006-6-20
|
pubmed:abstractText |
Differential gene expression studies are identifying new sets of genes with a role in the classification, differential diagnosis, and prognosis of some human tumors. Ephrin B1, a factor involved in angiogenesis, has been shown to be up-regulated in ovarian carcinomas, making it a potential target for cancer treatment. This study investigates ephrin B expression in ovarian tumors to validate results from gene expression studies and evaluates its significance with a clinical-pathological correlation. Specimens from 112 benign, borderline, and malignant epithelial ovarian tumors were examined. Tissue microarrays were constructed, and ephrin B expression was studied by immunohistochemistry. To correlate ephrin B expression with angiogenesis, CD31 immunostaining was performed to assess microvessel density. Ephrin B was detected in 50% of ovarian tumors: clear cell carcinomas (93%), serous carcinomas (74%), mucinous carcinomas (29%), and endometrioid carcinomas (27%). High-grade carcinomas showed greatest ephrin B expression, whereas benign tumors and low-grade carcinomas were rarely positive. A correlation was found between ephrin B expression and microvessel density, supporting the angiogenic role of this factor in ovarian carcinomas. Ephrin B expression was associated with higher rates of disease recurrence and a decrease in overall survival. A distinctive pattern of ephrin B expression was observed in ovarian tumors: high-grade tumors and clear cell and serous carcinomas show higher expression, correlating with the aggressiveness. On the other hand, ephrin B expression correlated with microvessel density of the tumors. Because Eph receptors and ephrins are targets for new therapeutic inhibitors, this pattern of ephrin B expression should be considered in future clinical studies.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0046-8177
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
37
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
883-9
|
pubmed:meshHeading |
pubmed-meshheading:16784989-Adult,
pubmed-meshheading:16784989-Aged,
pubmed-meshheading:16784989-Aged, 80 and over,
pubmed-meshheading:16784989-Blotting, Western,
pubmed-meshheading:16784989-Cell Differentiation,
pubmed-meshheading:16784989-Ephrin-B1,
pubmed-meshheading:16784989-Female,
pubmed-meshheading:16784989-Humans,
pubmed-meshheading:16784989-Immunohistochemistry,
pubmed-meshheading:16784989-Microcirculation,
pubmed-meshheading:16784989-Middle Aged,
pubmed-meshheading:16784989-Neovascularization, Pathologic,
pubmed-meshheading:16784989-Ovarian Neoplasms,
pubmed-meshheading:16784989-Survival Analysis,
pubmed-meshheading:16784989-Tumor Markers, Biological
|
pubmed:year |
2006
|
pubmed:articleTitle |
Ephrin B expression in epithelial ovarian neoplasms correlates with tumor differentiation and angiogenesis.
|
pubmed:affiliation |
Department of Pathology, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
|
pubmed:publicationType |
Journal Article
|